<?xml version="1.0" encoding="UTF-8"?>
<p>Referrals that were triggered following safety concerns of the antibiotics were excluded, such as the quinolone- and fluoroquinolone-containing medicinal products referral finalised in November 2018. This procedure was initiated because of serious, disabling and potentially permanent side effects of quinolone and fluoroquinolone antibiotics.</p>
